These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 26758586)

  • 61. An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel.
    Uchiyama T; Kanno H; Ishitani K; Fujii H; Ohta H; Matsui H; Kamatani N; Saito K
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1617-24. PubMed ID: 22562553
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy.
    Shitara K; Matsuo K; Oze I; Mizota A; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):301-7. PubMed ID: 20960191
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Hu X; Pu K; Feng X; Wen S; Fu X; Guo C; He W
    PLoS One; 2016; 11(3):e0149247. PubMed ID: 26954503
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Utility of Physiologically Based Pharmacokinetic Modeling to Investigate the Impact of Physiological Changes of Pregnancy and Cancer on Oncology Drug Pharmacokinetics.
    Yang X; Grimstein M; Pressly M; Fletcher EP; Shord S; Leong R
    Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140068
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A model-based meta-analysis of immune-related adverse events during immune checkpoint inhibitors treatment for NSCLC.
    Zhang R; Kong D; Chen R; Guo Y; Jian W; Han M; Zhou T
    CPT Pharmacometrics Syst Pharmacol; 2022 Aug; 11(8):1135-1146. PubMed ID: 35763678
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Applications of Model-Based Meta-Analysis in Drug Development.
    Chan P; Peskov K; Song X
    Pharm Res; 2022 Aug; 39(8):1761-1777. PubMed ID: 35174432
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Model-informed drug repurposing: A pharmacometric approach to novel pathogen preparedness, response and retrospection.
    Dodds M; Xiong Y; Mouksassi S; Kirkpatrick CM; Hui K; Doyle E; Patel K; Cox E; Wesche D; Brown F; Rayner CR
    Br J Clin Pharmacol; 2021 Sep; 87(9):3388-3397. PubMed ID: 33534138
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
    Qi WX; Shen Z; Yao Y
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
    Bria E; Cuppone F; Ciccarese M; Nisticò C; Facciolo F; Milella M; Izzo F; Terzoli E; Cognetti F; Giannarelli D
    Cancer Treat Rev; 2006 Dec; 32(8):583-7. PubMed ID: 16919884
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
    Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
    Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer.
    Stroh M; Green M; Cha E; Zhang N; Wada R; Jin J
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):485-94. PubMed ID: 26758586
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
    Ardizzoni A; Tiseo M
    J Chemother; 2004 Nov; 16 Suppl 4():104-7. PubMed ID: 15688623
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis.
    Wailoo A; Sutton A; Morgan A
    Br J Cancer; 2009 Feb; 100(3):436-41. PubMed ID: 19190633
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.